Avastin/sunitnib RCC trial closes after serious toxicities

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 8
Volume 17
Issue 8

The lead investigator in an evaluation of bevacizumab (Avastin) combined with sunitinib malate (Sutent) for renal cell carcinoma (RCC) said the project would be abandoned. FDA issued a product safety alert after Genentech, Avastin’s developer, reported serious complications in several patients enrolled in the phase I trial.

The lead investigator in an evaluation of bevacizumab (Avastin) combined with sunitinib malate (Sutent) for renal cell carcinoma (RCC) said the project would be abandoned. FDA issued a product safety alert after Genentech, Avastin’s developer, reported serious complications in several patients enrolled in the phase I trial.

“In my opinion, this particular trial is not going to go anywhere in renal cell cancer,” said Robert Motzer, MD, of Memorial Sloan-Kettering Cancer Center.

In its July 14 alert, FDA declared, “Avastin is not approved for use in combination with sunitinib malate, and this combination is not recommended.” The alert was based on a July 11 letter from Genentech to cancer care specialists.

Dr. Motzer told ONI that he was surprised by the complications, which included microangiopathic hemolytic anemia (MAHA) with severe hypertension. Initially, tumor response was excellent, and the full dose was reached without dose-limiting toxicity, he said. But over time, poor tolerance became apparent. All patients who developed MAHA recovered when the drug was terminated.

Poor tolerability that did not involve MAHA led Genentech to close two phase II trials of Avastin/sunitinib in NSCLC and metastatic breast cancer. Genentech spokesperson Kimberly Ocampo said the negative results would not affect the overall Avastin development program.

Dr. Motzer noted that the cases of MAHA in his study were observed in patients who received the highest dose level of sunitinib malate. “One could potentially look at alternative dosing strategies with very low doses or intermittent doses in clinical trials,” he said.

The phase I dose-escalation study involved 25 patients in three cohorts. Five of 12 patients received the highest sunitinib dose, and two of those subjects had severe MAHA.

Dr. Motzer theorized that the drugs may have caused a reaction in the blood vessel lining or that the complications may be unique to RCC patients. The trial marked the first time he had seen MAHA in RCC patients, he said.

Dr. Motzer noted that, despite the disappointing outcome, “this is the way the process is supposed to work. If there is a signal like this, we need to act on it. That’s exactly what we did in a strong fashion.”

Recent Videos
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.
The annual Kidney Cancer Research Summit was born from congressional funding for kidney cancer research, according to KidneyCAN president Bryan Lewis.
Combining renal vaccines with immune therapy may better target tumor cells while limiting harm to healthy tissue, according to David A. Braun, MD, PhD.
Improving data collection and biomarker development across institutions may represent areas of expansion in kidney cancer research.
KIM-1 is a biomarker in the blood that may help noninvasively detect kidney cancer, according to Wenxin (Vincent) Xu, MD.
A phase 0 trial is seeking to assess the feasibility of aiding anti-cancer cells with cytokines to restore their function.
Related Content